Glaukos Corporation (GKOS)
USD 145.14
(-0.83%)
USD 145.14
(-0.83%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 478.64 Million USD | 1.33% |
| 2022 | 472.37 Million USD | 2.13% |
| 2021 | 462.54 Million USD | 36.83% |
| 2020 | 338.05 Million USD | 132.93% |
| 2019 | 145.12 Million USD | 338.32% |
| 2018 | 33.11 Million USD | 19.82% |
| 2017 | 27.63 Million USD | 61.63% |
| 2016 | 17.09 Million USD | -20.37% |
| 2015 | 21.47 Million USD | -88.51% |
| 2014 | 186.92 Million USD | 3.89% |
| 2013 | 179.91 Million USD | 1174.39% |
| 2012 | 14.11 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 254.51 Million USD | -47.26% |
| 2024 Q1 | 482.6 Million USD | 0.83% |
| 2024 Q3 | 258.03 Million USD | 1.38% |
| 2023 Q3 | 470.97 Million USD | 0.65% |
| 2023 Q1 | 464.07 Million USD | -1.76% |
| 2023 Q2 | 467.92 Million USD | 0.83% |
| 2023 Q4 | 478.64 Million USD | 1.63% |
| 2023 FY | 478.64 Million USD | 1.33% |
| 2022 Q4 | 472.37 Million USD | 2.71% |
| 2022 Q2 | 468.8 Million USD | 3.15% |
| 2022 Q3 | 459.91 Million USD | -1.9% |
| 2022 Q1 | 454.5 Million USD | -1.74% |
| 2022 FY | 472.37 Million USD | 2.13% |
| 2021 Q1 | 433 Million USD | 28.09% |
| 2021 FY | 462.54 Million USD | 36.83% |
| 2021 Q4 | 462.54 Million USD | -0.12% |
| 2021 Q3 | 463.08 Million USD | 0.8% |
| 2021 Q2 | 459.4 Million USD | 6.1% |
| 2020 Q3 | 332.95 Million USD | -0.11% |
| 2020 Q4 | 338.05 Million USD | 1.53% |
| 2020 FY | 338.05 Million USD | 132.93% |
| 2020 Q1 | 138.42 Million USD | -4.62% |
| 2020 Q2 | 333.3 Million USD | 140.79% |
| 2019 Q4 | 145.12 Million USD | 23.7% |
| 2019 Q1 | 42.54 Million USD | 28.5% |
| 2019 Q3 | 117.32 Million USD | 2.66% |
| 2019 Q2 | 114.28 Million USD | 168.6% |
| 2019 FY | 145.12 Million USD | 338.32% |
| 2018 Q1 | 20.32 Million USD | -26.45% |
| 2018 Q4 | 33.11 Million USD | 22.21% |
| 2018 Q3 | 27.09 Million USD | 20.11% |
| 2018 Q2 | 22.55 Million USD | 10.98% |
| 2018 FY | 33.11 Million USD | 19.82% |
| 2017 Q1 | 14.94 Million USD | -12.56% |
| 2017 FY | 27.63 Million USD | 61.63% |
| 2017 Q4 | 27.63 Million USD | 34.73% |
| 2017 Q3 | 20.51 Million USD | 4.69% |
| 2017 Q2 | 19.59 Million USD | 31.06% |
| 2016 Q4 | 17.09 Million USD | -10.25% |
| 2016 Q2 | 18.96 Million USD | 3.84% |
| 2016 Q1 | 18.25 Million USD | -14.96% |
| 2016 FY | 17.09 Million USD | -20.37% |
| 2016 Q3 | 19.04 Million USD | 0.47% |
| 2015 Q1 | 32.21 Million USD | -82.76% |
| 2015 Q2 | 33.38 Million USD | 3.61% |
| 2015 FY | 21.47 Million USD | -88.51% |
| 2015 Q4 | 21.47 Million USD | -6.3% |
| 2015 Q3 | 22.91 Million USD | -31.36% |
| 2014 Q1 | 22.78 Million USD | -1.06% |
| 2014 FY | 186.92 Million USD | 3.89% |
| 2014 Q4 | 186.92 Million USD | 0.0% |
| 2014 Q2 | 23.48 Million USD | 3.08% |
| 2013 FY | 179.91 Million USD | 1174.39% |
| 2013 Q4 | 23.02 Million USD | 0.0% |
| 2013 Q3 | 23.02 Million USD | 0.0% |
| 2012 FY | 14.11 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Abbott Laboratories | 34.38 Billion USD | 98.608% |
| Allurion Technologies Inc. | 142.19 Million USD | -236.604% |
| Artivion, Inc. | 510.61 Million USD | 6.261% |
| Avanos Medical, Inc. | 456.1 Million USD | -4.944% |
| Butterfly Network, Inc. | 84.22 Million USD | -468.324% |
| Butterfly Network, Inc. | 84.22 Million USD | -468.324% |
| Bio-Rad Laboratories, Inc. | 3.55 Billion USD | 86.547% |
| Boston Scientific Corporation | 15.6 Billion USD | 96.933% |
| Perspective Therapeutics, Inc. | 3.44 Million USD | -13777.878% |
| CONMED Corporation | 1.46 Billion USD | 67.346% |
| Edwards Lifesciences Corporation | 2.64 Billion USD | 81.895% |
| Paragon 28, Inc. | 162.95 Million USD | -193.725% |
| Globus Medical, Inc. | 1.08 Billion USD | 56.012% |
| Inspire Medical Systems, Inc. | 104.29 Million USD | -358.928% |
| Integer Holdings Corporation | 1.41 Billion USD | 66.131% |
| Medtronic plc | 39.56 Billion USD | 98.79% |
| Nevro Corp. | 330.31 Million USD | -44.908% |
| Owlet, Inc. | 73.79 Million USD | -548.583% |
| Penumbra, Inc. | 377.36 Million USD | -26.841% |
| Vicarious Surgical Inc. | 21.89 Million USD | -2086.106% |
| Smith & Nephew plc | 4.77 Billion USD | 89.965% |
| Sonendo, Inc. | 49.74 Million USD | -862.281% |
| STERIS plc | 4.74 Billion USD | 89.92% |
| Stryker Corporation | 21.31 Billion USD | 97.755% |
| Vapotherm, Inc. | 132.95 Million USD | -260.018% |
| Zimmer Biomet Holdings, Inc. | 9 Billion USD | 94.687% |